Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Chris Marino

Neurology Fort Myers, FL Medical Doctor

NPI 1417950635 CMS profile 199950

12670 Whitehall Dr, Fort Myers, FL 33907

Open in the dashboard

General payments

$11,768

620 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Chris Marino of Fort Myers, FL is reported in the CMS Open Payments database as having received $11,768 across 620 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,147 100
2024 General $2,287 112
2023 General $2,196 107
2022 General $1,963 101
2021 General $1,297 78
2020 General $836 48
2019 General $1,042 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chris Marino
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Chris Marino were reported at $2,147. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Chris Marino Neurology median Middle half National median
2019 $1,042 $474 $118–$2,177 $163
2020 $836 $367 $82–$2,309 $114
2021 $1,297 $438 $104–$2,547 $132
2022 $1,963 $442 $103–$2,388 $149
2023 $2,196 $464 $119–$2,312 $160
2024 $2,287 $468 $119–$2,323 $164
2025 $2,147 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,438 84 payments
  2. UCB, Inc. $887 33 payments
  3. ACADIA Pharmaceuticals Inc $576 39 payments
  4. Lundbeck LLC $507 21 payments
  5. Novartis Pharmaceuticals Corporation $506 26 payments
  6. Ge Healthcare $414 23 payments
  7. Genzyme Corporation $412 17 payments
  8. Alexion Pharmaceuticals, Inc. $411 17 payments
  9. Genentech USA, Inc. $400 23 payments
  10. Pfizer Inc. $396 24 payments
  11. Other $5,821 313 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,672 613 payments
  2. Education $59 5 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $36 2 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $706 40 payments
  2. QULIPTA $668 36 payments
  3. Briviact $509 16 payments
  4. KESIMPTA $388 19 payments
  5. NUPLAZID $368 28 payments
  6. OCREVUS $349 21 payments
  7. ZEPOSIA $316 16 payments
  8. NURTEC ODT Pain $312 20 payments
  9. ULTOMIRIS $309 12 payments
  10. NURTEC ODT Primary Care $309 22 payments
  11. Other $8,105 430 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

1,613

Median for Neurology: 833

Drug cost

$3,012,039

Median for Neurology: $202,670

Branded share of claims

29.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Soliris Eculizumab Brand 18 $993,752
Firdapse Amifampridine Phosphate Brand 15 $806,680
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 22 $243,565
Austedo Deutetrabenazine Brand 22 $215,475
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 14 $196,653
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 12 $195,021
Copaxone Glatiramer Acetate Brand 25 $143,460
Vigabatrin Generic 13 $130,144
Aimovig Autoinjector Erenumab-Aooe Brand 25 $23,801
Nurtec Odt Rimegepant Sulfate Brand 11 $16,746

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$882,423

Of which drugs: $629,802

Medicare patients

920

Average age 76

Services billed

39,767

498 women, 422 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Ischemic heart disease 40%
Depression 35%
Diabetes 30%
Chronic kidney disease 28%
Atrial fibrillation 25%
COPD 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, incobotulinumtoxin a, 1 unit J0588 Office 18 10,800 $43,465
Injection, onabotulinumtoxina, 1 unit J0585 Office 25 8,200 $40,424
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 21 45 $40

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 40 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $203
$203 — —
ULTOMIRIS
  • Alexion Pharmaceuticals, Inc. $189
$189 — —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $160
$160 — —
RYTARY
  • Amneal Pharmaceuticals LLC $84
$84 — —
VYEPTI
  • Lundbeck LLC $84
$84 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 40 with Patron

Records

620 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record